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sychiatric diseases represent a major cause of dis-
ability among individuals during their peak years of pro-
ductivity (ages 15 to 44) and remain major causes of mor-
tality in the developed world.
1 Because of this,governments
and pharmaceutical companies have expended many bil-
lions of dollars on understanding the underlying causes of
mental illnesses,and on discovering new and more effec-
tive treatments for them(Roth and Conn, unpublished
report).The budget for the National Institute of Mental
Health (NIMH)—the major funding agency for mental
health-related research in the US—for the financial year
2006 stood at $1.4 billion, as stated on their Web site.
2
Despite this heavy investment,no psychiatric medications
with greater efficacy than drugs discovered 50 years ago
have yet appeared.
3,4Thus,for example,clozapine (which
was synthesized nearly 50 years ago
4) continues to be the
“gold standard”for treating schizophrenia.
5,6
The recent sequencing and continued annotation of the
human genome
7 and the tentative identification of a large
number of schizophrenia susceptibility genes
8 have raised
the possibility that molecular biology and its associated
technologies will lead to new and improved treatments
for schizophrenia and related disorders.
9The assumption
underlying this hope is that “we should finally make
rapid progress identifying some of the vulnerability genes
and thus critical pathways for the pathophysiology of the
major mental illnesses…”
1 The hypothesis is that if we
can understand the pathophysiological basis of these dis-
eases—based on their molecular neurobiological under-
pinning—we will be better able to develop curative ther-
apeutics (or “cure therapeutics”
1) for schizophrenia and
related disorders. Although this is a highly attractive
hypothesis, it is founded on a number of assumptions,
some of which are falsifiable,others of which are not (at
least with the available technology).In this review,this
hypothesis and its underlying assumptions will be exam-
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This review summarizes the various conceptual paradigms
for treating schizophrenia, and indicates how molecular
biology and drug discovery technologies can accelerate the
development of new medications. As yet, there is no con-
vincing data that a crucial druggable molecular target
exists which, if targeted, would yield medications with effi-
cacies greater than any currently available. It is suggested,
instead, that drugs which interact with a multiplicity of
molecular targets are likely to show greater efficacy in
treating the core symptoms of schizophrenia.
© 2006, LLS SAS Dialogues Clin Neurosci. 2006;8:303-309.ined,and suggestions will be put forward as to how mol-
ecular biology can (and cannot) provide tests of this
hypothesis,as well as possibilities for novel medications
for curative therapeutics of schizophrenia and related
disorders.
Schizophrenia as a molecular disease
Currently,at least three overlapping paradigms drive the
drug discovery effort for schizophrenia.These include,
firstly,the molecular-genetic hypotheses which hypothe-
size strong effects of schizophrenia susceptibility genes.
8
A corollary of the molecular-genetic hypothesis is the
proposal that targeting drugs at these genes might yield
novel and more effective treatments for schizophrenia.
1,10
Secondly, the neuronal network hypotheses propose
strong effects of altered neuronal integration in schizo-
phrenia.The corollary of this hypothesis predicts that
drugs which fundamentally reset the tone of networks of
neuronal interactions will prove efficacious in treating
schizophrenia.
4,11Thirdly,the signal transduction hypoth-
esis proposes that basic alterations in receptor-mediated
signal transduction (either at the receptor or post-recep-
tor levels) induce schizophrenia-like pathology.It follows
that ameliorating altered signaling via specific medica-
tions which target receptor/post-receptor molecules will
prove efficacious in treating schizophrenia.
12-16
These general hypotheses are highly interconnected and
interdependent.Thus,one could suggest,for instance,that
schizophrenia arises because of mutation in a specific sus-
ceptibility gene—α7 nicotinic receptors for instance.
17
This mutation results in diminished α7 expression
18
which,in turn,leads to altered neuronal connectivity and
signal transduction.
17These alterations in neuronal sig-
naling and connectivity lead to some of the symptoms of
schizophrenia.The corollary is the proposal that α7 ago-
nists will improve schizophrenia symptoms
19—a hypoth-
esis that is now being tested.
The underlying assumption of these lines of reasoning is
that if one can identify the critical node (Figure 1) in the
pathogenesis of schizophrenia and alter its functioning,
one will more effectively treat schizophrenia.The implicit
assumption is that only one (or a small number) of mol-
ecular targets function as critical nodes in the pathogen-
esis of schizophrenia.The role of molecular biology in
such an undertaking is relatively straightforward:(i) iden-
tify the “disease-inducing molecules” (genetic linkage
studies,candidate gene approaches);(ii) express the mol-
ecule in a way suitable for high-throughput-screening of
large chemical libraries to identify candidate ligands with
appropriate pharmacology (agonist,antagonist,partial
agonist,inverse agonist,allosteric modulator
20);(iii) pro-
vide molecular-target based assays for profiling candidate
ligands at a large variety of other druggable targets to
verify that the final lead compounds are suitably selec-
tive (or suitably nonselective
3,21);and (iv) provide mole-
cular-target based assays for profiling candidate ligands
against various molecular targets which can lead to seri-
ous side effects.These can include prolongation of the Q-
T interval via blockade of HERG K
+-channels,
22 agonism
of 5-HT2B serotonin receptors which can lead to cardio-
vascular side effects,
23 carcinogenicity,genotoxicity,and
alteration of cytochrome P450 isoforms leading to altered
pharmacokinetics (see ref 24 for instance).In the case of
antipsychotic medications,weight gain and adverse meta-
bolic side effects (likely mediated in part via H1-hista-
mine and 5-HT2C-serotonin receptor blockade
34) and
extrapyramidal side effects (due to D2-dopamine recep-
tor blockade) occur frequently.Indeed,much of preclin-
ical drug discovery in both industry and academia is dri-
ven primarily via molecular target-based screening and
profiling technologies.Despite our ability to screen mil-
lions of drug-like compounds at hundreds of druggable
targets which comprise the “druggable genome,”
25,26 no
novel molecularly targeted treatments for schizophrenia
have been approved. Indeed, as already mentioned,
clozapine continues to be the “gold-standard treatment”
for schizophrenia.
The critical node assumption has not (yet)
yielded better drugs for schizophrenia
Based on the “critical node”assumption,a large number
of potential nodes have been identified for therapeutic
drug discovery.These have been identified via the three
general strategies outlined above (eg,molecular genetic,
neuronal network, or signal transduction) and a large
number of these candidate nodes have been a theme of
research over the past decade.As we have recently sum-
marized as part of a larger study of psychiatric drug dis-
covery,nearly 150 investigational compounds directed
against many individual molecular targets (“nodes”)
have been subjected to at least early-phase clinical trials
(Roth and Conn, unpublished report). Representative
compounds for each node are listed in Table I. In this
table,antipsychotic drugs have been classified based on
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whether the compounds were validated with preclinical
and clinical studies. Lastly, it is indicated whether the
compounds were found, based on clinical trials, to be
superior to a standard comparator medication (typically
haloperidol).Based on the currently available data,we
were unable to find any evidence to support the hypoth-
esis that targeting any single molecular target (“node”)
other than D2 dopamine receptors will yield a drug which
effectively treats the core symptoms of schizophrenia.
Additionally,we were unable to find any support for the
hypothesis that drugs targeting a single node are more
effective at treating schizophrenia than drugs targeting a
large number of nodes.Indeed,clozapine,which targets
at least 50 nodes,remains superior to all other medica-
tions.
3,5The results obtained are consistent with the pro-
posal that “D2 dopamine receptors represent the critical
node in schizophrenia pathogenesis.”
13 It is unknown
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Figure 1. Schizophrenia susceptibility genes are localized in overlapping neuronal pathways. Shown in diagrammatic form are the presumed local-
izations of various schizophrenia susceptibility gene products in a model synapse in the prefrontal cortex. As shown, a typical pyramidal
neuron fiber receives inputs from dopaminergic, serotonergic, glutamatergic, and GABA-ergic neurons. The various susceptibility genes
indicated may modulate pre- or postsynaptic glutamatergic functioning. Antipsychotic drugs mainly affect biogenic amine receptor activ-
ities which may be either pre- or postsynaptic in nature. GABA, γ-aminobutyric acid
Susceptibility genes
• Dysbindin
• Neuregulin-1
• DISC1
• RGS-4
• G72
• COMT
• REELINwhether any single molecular target of greater promise
will ever be found.
There are many ways in which these findings can be
interpreted,although each interpretation relies mainly
on untested assertions.A typical criticism one can make
of these findings is that “we have not yet found the crit-
ical node”and that once this key node is discovered,the
pathway towards drugs with greater efficacy and fewer
side effects will be clarified.The untested assumptions
are (i) that such a special node associated with efficacy
exists;(ii) that it can be discovered;and (iii) that,once
discovered,using techniques of molecular biology,a drug
can be designed to target it. An implicit assumption
underlying this argument relates to the need for an
enhanced understanding of the molecular pathogenesis
of schizophrenia in order to discover and validate suit-
able molecular targets.
1,9
Based upon our current understanding of the molecular
pathogenesis of schizophrenia, no critical node other
than the D2 dopamine receptor has yet been convincingly
and reproducibly elucidated,although a large number of
candidate genes and susceptibility factors have been
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Table I. Multiple candidate nodes have been subjected to testing as targets for treating schizophrenia. This shows an abstracted analysis from a
recent study
2 examining the evidence for and against various molecular-target based approaches for treating schizophrenia. *, various
animal models which have been tested and for which the drug has efficacy; **, clinical trials are ongoing and information is not available;
***, dropped from development with no further data available; EPS, extrapyramidal syndrome.
Node (molecular target) Representative  Preclinical  Results from  Efficacy >  Side effects
drug evidence randomized haloperidol
of efficacy* clinical trials
D2 dopamine antagonist Haloperidol, Many Effective Equivalent EPS
amisulpride
D2 dopamine partial agonist Aripiprazole Many Effective Equivalent Activation
Highly promiscuous antagonist Clozapine Many Effective More effective Agranulocytosis, 
(40+ nodes) weight gain, 
sedation, seizures
Moderately promiscuous Olanzapine Many Effective Equivalent Weight gain, sedation
antagonist (20+ nodes)
Mildly promiscuous  Risperidone Many Effective Equivalent Weight, gain, sedation, 
antagonist (10-20 nodes) ? EPS with higher doses
Promiscuous agonist N-desemethyl-clozapine Many Unknown Unknown Unknown
(40+nodes;partial agonist at >3)
5-HT2A antagonist SR46349B Many Possibly effective Possibly equivalent Minimal
NK-3 antagonist  SR142801 Partial Possibly effective (clinical Equivalent Minimal
development ceased)
D4 antagonist  Belaperidone Partial No No Worsening of psychosis?
D3 antagonist LU-201640 Partial Ongoing** Ongoing Ongoing
D1 antagonist BSF-78438 Partial Dropped*** Dropped Dropped
Sigma-1 antagonist  BMY 14802 Partial Ineffective Ineffective Perhaps worsening 
of psychosis
AMPA 1 glutamate modulator Org-24448 Partial Ongoing Ongoing Ongoing
mGluR2 glutamate agonist LY-341495 Partial Ongoing Ongoing Ongoing
CB-1 cannibinoid antagonist  SR141716 Partial Ineffective Ineffective Dropped
NT-1 neurotensin antagonist  SR48692 Partial Ineffective Ineffective Dropped
α7-Nicotinic agonist/partial agonist MEM-3454 Partial Ongoing Ongoing Ongoing
NMDA glutamate modulator D-serine Partial Perhaps partially effective Ongoing Ongoing
PDE10A antagonist  Papaverine Partial Unknown Unknown Unknown
α2-Adrenergic agonist Clonidine Partial Perhaps partial  Unknown Unknown
as augmentationdescribed.These include neuregulin-1,
27 dysbindin,
28 dis-
rupted in schizophrenia-1 (DISC-1)
29 and many others
(eg, reelin, regulator of G protein signaling-4, catechol-
O-methyltransferase, mGluR3 glutamate receptor, and
so on; see ref 8 for recent review).As we
3 and others
30
have pointed out (Figure 1) these susceptibility gene
products are found in a variety of cell types (both neu-
ronal and glial) and show differential subcellular local-
izations.As Figure 1 shows, the molecular targets iden-
tified are frequently found in circuits which are targeted
by drugs with a “promiscuous”pharmacology (eg,cloza-
pine).No single node is an obvious target for therapeu-
tic drug discovery efforts,although nearly all of the iden-
tified nodes have been reported to be targets of
therapeutic drug discovery (Roth and Conn, unpub-
lished report).
Another possibility is that schizophrenia can be most
effectively treated by influencing several nodes simulta-
neously.
3 Indeed,based on the demonstrated superiority
of clozapine for treatment-resistant schizophrenia
5 and
the relative inferiority of all other medications,
6 there is
strong support for this hypothesis.A great deal of effort
has been expended to discover an optimal clozapine-
mimetic devoid of the side effects of clozapine which
include agranulocytosis,seizures,sialorrhea,weight gain,
sedation, and hypotension. We, and others, have sug-
gested that the massively parallel screening of large num-
bers of molecular targets allows one to efficiently dis-
cover “toxic”vs “therapeutic”targets.
32-34Antipsychotic
drug-induced weight gain might be due to H1-histamine
and 5-HT2C-receptor blockade,
35,36 agranulocytosis to H4
histamine agonism,
2 sedation to H1 histamine antago-
nism,
4 and so on.Thus far,these molecular targets impli-
cated in clozapine’s side effects (H1-histamine,H4-hista-
mine, 5-HT2C serotonin) are not identical with those
targets thought to be involved in its superiority as an
antipsychotic drug (5-HT2A serotonin,D4-dopamine,5-
HT6 and 5-HT7 serotonin).A problem with the approach
of designing selectively nonselective drugs is that it is
very difficult to rationally design in new pharmacologi-
cal properties during the drug discovery process.
24This is
an emerging paradigm, however, and some successful
strategies have recently been elucidated.
37
A systems level approach
The neuronal systems approach similarly proposes that
there might be crucial nodes in the network that are
amenable to target-based discovery efforts.
4 Spedding and
colleagues have cogently argued that a systems-level
approach using animal models will lead to more effective
treatment for psychiatric diseases.
4 Based on a model
which involves specific alterations in hippocampal-corti-
cal circuitry,they propose testing compounds in animals in
which these circuits are disrupted by phenycyclidine
(PCP).In support of this systems-level approach,nearly
every approved antipsychotic drug will ameliorate PCP-
induced alterations in neuronal functioning.
37 However,it
is also true that drug classes with demonstrated ability to
ameliorate PCP-induced deficits (eg,5-HT2A antagonists
38)
are only marginally effective in treating schizophrenia.
39,40
Thus,in vivo systems-level screens can be highly effective
tools to verify in vivo actions of putative atypical antipsy-
chotic drugs.It does not appear that any of the available
in vivo screening models are able to predict relative effi-
cacy at treating schizophrenia,however.In addition,none
of the available models appears to adequately recapitulate
the entirety of the human phenotype.
37
One can easily provide the counterargument that a “suit-
able animal model will eventually be found which reca-
pitulates the schizophrenia phenotype,”although it is also
plausible that “no suitable preclinical model will ever be
found which adequately recapitulates schizophrenia
pathology.”Clearly,despite decades of research we have
not yet discovered an adequate preclinical model,and it
is within the realm of possibility that “schizophrenia is a
uniquely human disease which cannot be adequately
modeled in rodents.”In large measure,this is likely to be
due to the fact that a number of genetic “hits”as well as
nongenomic factors converge to produce the final phe-
notype in humans.
41At present,we have no way to pre-
dict either way,and continued research in this arena will
be based more on untested assumptions than on data.
Is schizophrenia similar to hypertension in
being complex, polygenic, and epigenetic?
Another possibility is that schizophrenia represents a
complex disease with genetic and epigenetic factors and
which is both chronic and progressive,resulting in irre-
versible end-organ damage—similar to hypertension.
Indeed,there is accumulating evidence for epigenetic fac-
tors involved in the etiology of schizophrenia—particu-
larly relating to reelin.
42-45There has also been abundant
evidence accumulated over the past several decades that
schizophrenia is associated with subtle but reproducibly
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Accordingly,optimal treatment of schizophrenia would
be similar to that for other progressive and complex dis-
eases such as hypertension, where individuals at risk
would be identified and then treated to avoid end-organ
damage.Such an approach has already been attempted,
with a mixed degree of success.
48 In this study,individu-
als at risk were identified and then prophylactically
treated with placebo or olanzapine.Although the results
were not statistically significant,there was a trend toward
protection of conversion to overt psychosis among indi-
viduals treated with olanzapine.
48
Conclusion
As is clear from the foregoing, the tools of molecular
biology can, at least theoretically, accelerate drug dis-
covery in schizophrenia.In the main,molecular biologi-
cal approaches have been more useful in providing
reagents for high-throughput screening campaigns than
for providing better animal models—at least to date.
With the continued discovery of schizophrenia suscep-
tibility genes, it is at least conceivable that better pre-
clinical models will be produced.To a great degree,lack
of progress in developing more effective antipsychotic
drugs has stemmed mainly from the failure both to fully
appreciate the pharmacological robustness of clozapine
and to discover medications which reproduce the essen-
tial features without producing serious side effects.It is
not clear whether any of the paradigms outlined will lead
to more effective medications,although it is likely that
continued molecular target-based screening will eventu-
ally yield medications with fewer side effects. ❏
The work from the author’s lab was supported entirely by grants from the
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Contribuciones de la biología molecular al
descubrimiento de fármacos antipsicóticos:
¿promesas cumplidas o incumplidas?
Esta revisión resume los diversos paradigmas con-
ceptuales que existen para el tratamiento de la
esquizofrenia e indica cómo la biología molecular
y las tecnologías para el descubrimiento de fárma-
cos pueden acelerar el desarrollo de nuevos medi-
camentos. Aun no se dispone de información con-
vincente acerca de la existencia de una molécula
específica, que pueda transformarse en un medica-
mento, y que de encontrarse pueda dar origen a
fármacos más eficaces que cualquiera de los actual-
mente disponibles. Se sugiere, en cambio, que es
probable que fármacos que interactúan con una
multiplicidad de blancos moleculares muestren
mayor eficacia en el tratamiento de los síntomas
centrales de la esquizofrenia. 
Apports de la biologie moléculaire à la 
découverte des médicaments 
antipsychotiques : promesses tenues ou non ?
Cet article résume les différents modèles concep-
tuels de traitement de la schizophrénie et montre
comment la biologie moléculaire et les technolo-
gies de découverte des médicaments peuvent accé-
lérer le développement de nouveaux traitements.
Nous ne disposons pas encore de données convain-
cantes sur l’existence d’une molécule décisive, trans-
formable en médicament qui, si elle était choisie,
déboucherait sur des traitements plus efficaces que
ceux disponibles actuellement.  Il est plutôt suggéré
que les médicaments interagissant avec les nom-
breuses cibles moléculaires seraient plus efficaces
dans le traitement des symptômes clés de la schi-
zophrénie.